Patients with alcoholism, anxiety and one copy of the CYP3A4*22 allele in combination with one copy of hte *1 allele may have a decreased response to alprazolam, as measured by changes in HAMA scores, as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to alprazolam.